Luc Cormier
Overview
Explore the profile of Luc Cormier including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
76
Citations
1107
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Escoffier A, Delattre B, Bettler L, Bontemps G, Cormier L
Fr J Urol
. 2024 Dec;
35(2):102844.
PMID: 39645149
Introduction: Penectomy, whether partial (PP) or radical (RP), are mainly performed for oncological reason. It is a rare but impactful surgery, with significant bio-psycho-social consequences. As some countries moves towards...
2.
Baude J, Niogret J, Jacob P, Bardet F, Desmoulins I, Zanetta S, et al.
Cancers (Basel)
. 2024 Jan;
16(2).
PMID: 38254771
Background: Chemotherapy using carboplatin and etoposide (CE) is frequently pragmatically proposed to treat metastatic prostate cancer (mPC), both primary small-cell neuroendocrine (PSC-NE) carcinoma and adenocarcinoma with or without neuroendocrine (NE)...
3.
Lejeune C, Bourredjem A, Binquet C, Cussenot O, Boudrant G, Papillon F, et al.
World J Urol
. 2023 May;
41(6):1541-1549.
PMID: 37173454
Purpose: In diseases where there is no real consensus regarding treatment modalities, promoting shared decision-making can contribute to improving safety and quality of care. This is the case in low-...
4.
Cassin J, Walker P, Blanc J, Asuncion A, Bardet F, Cormier L, et al.
Quant Imaging Med Surg
. 2023 Mar;
13(3):1440-1452.
PMID: 36915312
Background: The purpose of our study was to assess preoperative clinical biological and Magnetic Resonance Imaging (MRI) predictive factors of early biochemical failure (BF), defined as persistence of significant post-operative...
5.
Pasquier D, Lacornerie T, Supiot S, Pommier P, Quivrin M, Simon J, et al.
Eur Urol Oncol
. 2023 Feb;
6(4):399-405.
PMID: 36754722
Background: There is no consensus on the best local salvage treatment for prostate cancer recurrence after primary external beam radiotherapy. Prospective data on stereotactic body radiation therapy (SBRT) are very...
6.
Asuncion A, Walker P, Bertaut A, Blanc J, Labarre M, Martin E, et al.
Quant Imaging Med Surg
. 2022 Dec;
12(12):5309-5325.
PMID: 36465820
Background: To assess whether data from pre-therapeutic multiparametric magnetic resonance imaging (mpMRI) combined with three-dimensional magnetic resonance spectroscopy (3D MRS) provide prognostic factors of biochemical relapse in patients with localized...
7.
Marechal E, Jaugey A, Tarris G, Paindavoine M, Seibel J, Martin L, et al.
Clin J Am Soc Nephrol
. 2021 Dec;
17(2):260-270.
PMID: 34862241
Background And Objectives: The prognosis of patients undergoing kidney tumor resection or kidney donation is linked to many histologic criteria. These criteria notably include glomerular density, glomerular volume, vascular luminal...
8.
Deal M, Bardet F, Walker P, Vega M, Cochet A, Cormier L, et al.
Quant Imaging Med Surg
. 2021 Aug;
11(8):3749-3766.
PMID: 34341747
Background: The limitations of the assessment of tumor aggressiveness by Prostate Imaging Reporting and Data System (PI-RADS) and biopsies suggest that the diagnostic algorithm could be improved by quantitative measurements...
9.
Mejean A, Ravaud A, Thezenas S, Chevreau C, Bensalah K, Geoffrois L, et al.
Eur Urol
. 2021 Jun;
80(4):417-424.
PMID: 34187771
Background: The CARMENA trial in patients with metastatic renal cell carcinoma (mRCC) demonstrated that treatment with sunitinib alone was noninferior to cytoreductive nephrectomy (CN) followed by sunitinib (nephrectomy⬜sunitinib). Objective: The...
10.
Cancel M, Castellier C, Debiais-Delpech C, Charles T, Rozet F, Rioux-Leclercq N, et al.
Urol Oncol
. 2020 Aug;
39(1):74.e17-74.e23.
PMID: 32739231
Objectives: To determine whether small cell neuroendocrine prostate cancers (NEPCa) emerging after anti-androgen treatments are different from the rarest cases diagnosed de novo, and to identify effective predictive markers. Material...